This author has yet to write their bio.Meanwhile lets just say that we are proud Reuters Health contributed a whooping 7321 entries.
J&J’s large pharmaceuticals business is its major profit engine and the company is betting on that and its devices unit as the healthcare conglomerate prepares to spin off its consumer health business by the end of this year.
The letter sent to the European Medicines Agency comes as antibiotics, including amoxicillin – used to treat bacterial infections and often prescribed for ear and chest infections in children – have been in short supply since October.
The company plans to expand its manufacturing capacity at the Research Triangle Park facility in North Carolina to support increased demand for its key diabetes drugs. It has been struggling to meet high demand for the drugs Trulicity and Mounjaro, especially due to production of multiple dosage forms for each of them.
The program, named RxPass, includes more than 50 medications addressing over 80 chronic conditions such as high blood pressure, anxiety, diabetes, and male pattern baldness.
Last year more than 300 children – mainly aged under 5 – died of acute kidney injury, deaths that were associated with contaminated medicines, the WHO said in a statement.
The U.S. health regulator proposed the use of one dose of the latest updated COVID-19 shot annually for healthy adults, similar to the influenza immunization campaign, as it aims to simplify the country’s current COVID-vaccine strategy.
The European Cancer Imaging Initiative is an effort to speed up innovation and early cancer diagnosis using artificial intelligence.
In a filing in Manhattan federal court, the Federal Trade Commission said Shkreli has not complied with its requests for information relating to Druglike Inc., a company it said he formed last July, and noted his apparent failure to pay any of a $64.6 million penalty that accompanied the ban.
The subvariant is estimated to have accounted for 49.1% of COVID cases in the country in the week ended Jan. 21, compared with 37.2% estimated last week.
U.S. government plans to rein in drug prices could discourage work in some of Novartis’s most promising areas of research, the Swiss drugmaker warned, urging Washington to rethink the “unintended” effects of its new rules.